Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Overview
Choosing between the diversified stability of Johnson & Johnson (NYSE:JNJ) and the rapid growth trajectory of Eli Lilly & Co (NYSE:LLY) is a primary consideration for many healthcare investors in 2026.
Johnson & Johnson provides a broad foundation through drugs and medical devices, while Eli Lilly & Co focuses on blockbuster treatments for diabetes and obesity. They are being compared because they represent two different paths to success within the healthcare stocks universe, appealing to either value-oriented or growth-seeking investors.
Details
Johnson & Johnson operates through two primary segments, focusing on innovative medicine and its diverse portfolio of medical device stocks. The company reaches a global audience of hospitals, wholesalers, and healthcare professionals while collaborating with partners like AbbVie (NYSE:ABBV) to co-commercialize key oncology treatments. These strategic alliances and internal research efforts allow it to maintain a dominant presence in immunology, neuroscience, and cardiovascular health.
Source
Originally published at www.fool.com.